Lightweight Strategy for XOR PUFs as Security Primitives for Resource-constrained IoT device

Physical Unclonable Functions (PUFs) are promising security primitives for resource-constrained IoT devices. And the XOR Arbiter PUF (XOR-PUF) is one of the most studied PUFs, out of an effort to improve the resistance against machine learning attacks of probably the most lightweight delay-based PUFs - the Arbiter PUFs. However, recent attack studies reveal that even XOR-PUFs with large XOR sizes are still not safe against machine learning attacks. Increasing PUF stages or components and using different challenges for different components are two ways to improve the security of APUF-based PUFs, but more stages or components lead to more hardware cost and higher operation power, and different challenges for different components require the transmission of more bits during operations, which also leads to higher power consumption. In this paper, we present a strategy that combines the choice of XOR Arbiter PUF (XOR-PUF) architecture parameters with the way XOR-PUFs are used to achieve lightweights in hardware cost and energy consumption as well as security against machine learning attacks. Experimental evaluations show that with the proposed strategy, highly lightweight component-differentially challenged XOR-PUFs can withstand the most powerful machine learning attacks developed so far and maintain excellent intra-device and inter-device performance, rendering this strategy a potential blueprint for the fabrication and use of XOR-PUFs for resource-constrained IoT applications.Comment: arXiv admin note: text overlap with arXiv:2206.0131

Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas

Genetically modified T-cell immunotherapies are revolutionizing the therapeutic options for hematological malignancies, especially those of B-cell origin. Impressive efficacies of CD19-directed chimeric antigen receptor (CAR)-T therapy have been reported in refractory/relapsed (R/R) B-cell non-Hodgkin lymphoma (NHL) patients who were resistant to current standard therapies, with a complete remission (CR) rate of approximately 50%. At the same time, problems of resistance and relapse following CAR-T therapy have drawn growing attention. Recently, great efforts have been made to determine various factors that are connected to the responses and outcomes following CAR-T therapy, which may not only allow us to recognize those with a higher likelihood of responding and who could benefit most from the therapy but also identify those with a high risk of resistance and relapse and to whom further appropriate treatment should be administered following CAR-T therapy. Thus, we concentrate on the biomarkers that can predict responses and outcomes after CD19-directed CAR-T immunotherapy. Furthermore, the mechanisms that may lead to treatment failure are also discussed in this review